June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy, subretinal tissue plasminogen activator, air tamponade, and anti-VEGF
Author Affiliations & Notes
  • Yuki Morizane
    Ophthalmology, Okayama Univ Graduate School of Medicine, Okayama, Japan
  • Shuhei Kimura
    Ophthalmology, Okayama Univ Graduate School of Medicine, Okayama, Japan
  • Mio Hosokawa
    Ophthalmology, Okayama Univ Graduate School of Medicine, Okayama, Japan
  • Yusuke Shiode
    Ophthalmology, Okayama Univ Graduate School of Medicine, Okayama, Japan
  • Shinichiro Doi
    Ophthalmology, Okayama Univ Graduate School of Medicine, Okayama, Japan
  • Masayuki Hirano
    Ophthalmology, Okayama Univ Graduate School of Medicine, Okayama, Japan
  • Ryo Matoba
    Ophthalmology, Okayama Univ Graduate School of Medicine, Okayama, Japan
  • Mika Hosogi
    Ophthalmology, Okayama Univ Graduate School of Medicine, Okayama, Japan
  • Atsushi Fujiwara
    Ophthalmology, Okayama Univ Graduate School of Medicine, Okayama, Japan
  • Fumio Shiraga
    Ophthalmology, Okayama Univ Graduate School of Medicine, Okayama, Japan
  • Footnotes
    Commercial Relationships Yuki Morizane, None; Shuhei Kimura, None; Mio Hosokawa, None; Yusuke Shiode, None; Shinichiro Doi, None; Masayuki Hirano, None; Ryo Matoba, None; Mika Hosogi, None; Atsushi Fujiwara, None; Fumio Shiraga, Alcon (F), Byer (F), Novartis Pharma (F), Santen Pharmaceutical (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2851. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Yuki Morizane, Shuhei Kimura, Mio Hosokawa, Yusuke Shiode, Shinichiro Doi, Masayuki Hirano, Ryo Matoba, Mika Hosogi, Atsushi Fujiwara, Fumio Shiraga; Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy, subretinal tissue plasminogen activator, air tamponade, and anti-VEGF. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2851.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate vitrectomy with subretinal tissue plasminogen activator (t-PA) injection, and air tamponade, followed by intravitreal anti-vascular endothelial growth factor (VEGF) therapy for submacular hemorrhage (SMH) in polypoidal choroidal vasculopathy (PCV).

Methods: Fifteen eyes of 15 consecutive patients who underwent vitrectomy with subretinal t-PA injection, and air tamponade, followed by intravitreal anti-VEGF therapy for SMH due to PCV were studied. Patients with SMH due to other macular diseases, such as high myopia, typical AMD, retinal angiomatous proliferation, and angioid streaks, were excluded. To displace the SMH from the macula, 25-gauge micro-incision vitrectomy, subretinal injection of 4,000 IU t-PA (Cliactor, Eizai, Japan) in 0.1ml using a 38-gauge subretinal infusion needle (MedOne, Sarasota, FL), and fluid-air exchange were performed. The patients remained facedown for 3 days after surgery. Intravitreal injections of anti-VEGF reagents of either 0.5 mg ranibizumab (Genentech, Inc., South San Francisco, CA) or 0.5 mg aflibercept (Bayer, Basel, Switzerland) were performed pro re nata when exudative and/or hemorrhagic changes occurred after surgery. Main outcome measures were SMH displacement from the macula and changes in best-corrected visual acuity (BCVAs).

Results: Mean time from onset to surgery was 9.5 ± 4.5 (range, 5-21) days. Mean follow-up period was 9.4 ± 3.1 (range, 6-17) months. Surgery successfully displaced SMHs from the macula in all eyes. Mean BCVA (logMAR) at base line (0.98 ± 0.44) had improved significantly both 1 month after surgery (0.41 ± 0.25, P<0.01) and at final visits (0.23 ± 0.25, P<0.001). In all eyes, exudative retinal changes relapsed after surgery, but were completely resolved by anti-VEGF injections (mean number, 3.5 ± 1.9). No complications occurred in any patients.

Conclusions: Treating SMH with vitrectomy and subretinal t-PA injection, followed by intravitreal anti-VEGF therapy, is a safe and very effective strategy for improving visual acuity in PCV patients.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×